Skip to main content

Advertisement

Log in

High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

The upregulated expression of JMJD6 was observed in various human cancers. However, little was known about JMJD6 expression and its clinicopathological significance in lung adenocarcinoma. The aim of this study was to investigate the expression and significance of JMJD6 in lung adenocarcinoma progression and prognosis. The levels of JMJD6 mRNA and protein in lung adenocarcinoma specimens and corresponding non-tumorous lung tissues were evaluated by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blot. In order to investigate the correlations between JMJD6 and the clinicopathological features of lung adenocarcinoma, the expression of JMJD6 in 154 patients with lung adenocarcinoma was detected by immunohistochemistry. By qRT-PCR and Western blot, the relative expression levels of JMJD6 mRNA and protein were significantly higher in lung adenocarcinoma tissues than in corresponding non-tumorous lung tissues (P < 0.001). Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001). Moreover, the results of Kaplan–Meier analysis indicated that a high expression level of JMJD6 resulted in a significantly poor prognosis of lung adenocarcinoma patients. Multivariate analysis showed that the status of JMJD6 expression was an independent prognostic factor for lung adenocarcinoma patients. Our results showed that JMJD6 plays a key role in lung adenocarcinoma and therefore may provide an opportunity for developing a novel therapeutic target as well as a prognostic marker in lung adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi:10.3322/caac.20073.

    Article  PubMed  Google Scholar 

  2. Yatabe Y, Borczuk AC, Powell CA. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer. 2011;74:7–11. doi:10.1016/j.lungcan.2011.05.021.

    Article  PubMed  Google Scholar 

  3. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21:S16–22. doi:10.1038/modpathol.3801018.

    Article  PubMed  CAS  Google Scholar 

  4. Piperi C, Vlastos F, Farmaki E, Martinet N, Papavassiliou AG. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med. 2008;12:1495–501. doi:10.1111/j.1582-4934.2008.00309.x.

    Article  PubMed  CAS  Google Scholar 

  5. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–28. doi:10.2353/ajpath.2009.080874.

    Article  PubMed  CAS  Google Scholar 

  6. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 2007;8:829–33.

    Article  PubMed  CAS  Google Scholar 

  7. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer. 2008;123:1–7. doi:10.1002/ijc.23605.

    Article  PubMed  CAS  Google Scholar 

  8. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 2000;405:85–90. doi:10.1038/35011084.

    Article  PubMed  CAS  Google Scholar 

  9. Hahn P, Wegener I, Burrells A, Böse J, Wolf A, Erck C, et al. Analysis of Jmjd6 cellular localization and testing for its involvement in histone demethylation. PLoS One. 2010;5:e13769. doi:10.1371/journal.pone.0013769.

    Article  PubMed  Google Scholar 

  10. Boeckel JN, Guarani V, Koyanagi M, Roexe T, Lengeling A, Schermuly RT, et al. Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proc Natl Acad Sci U S A. 2011;108:3276–81. doi:10.1073/pnas.1008098108.

    Article  PubMed  CAS  Google Scholar 

  11. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, et al. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science. 2009;325:90–3. doi:10.1126/science.1175865.

    Article  PubMed  CAS  Google Scholar 

  12. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, et al. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. 2012;14:R85. doi:10.1186/bcr3200.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jin-Lin Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, J., Ni, SS., Zhao, WL. et al. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma. Tumor Biol. 34, 2397–2401 (2013). https://doi.org/10.1007/s13277-013-0789-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0789-9

Keywords

Navigation